Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
or

Merck & Company (MRK)

Merck & Company (MRK)
77.46 -0.54 (-0.69%) 11:19 ET [NYSE]
77.43 x 50 77.46 x 206
Realtime by (Cboe BZX)
77.43 x 50 77.46 x 206
Realtime 77.64 -0.36 (-0.46%) 09:00 ET
Quote Overview for Mon, Apr 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
77.30
Day High
78.19
Open 78.08
Previous Close 78.00 78.00
Volume 1,555,837 1,555,837
Avg Vol 16,436,311 16,436,311
Stochastic %K 14.67% 14.67%
Weighted Alpha -43.00 -43.00
5-Day Change -1.16 (-1.47%) -1.16 (-1.47%)
52-Week Range 75.93 - 134.63 75.93 - 134.63
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 196,697,200
  • Shares Outstanding, K 2,521,759
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 20,221 M
  • EBITDA $ 24,720 M
  • 60-Month Beta 0.40
  • Price/Sales 3.00
  • Price/Cash Flow 8.08
  • Price/Book 4.17

Options Overview Details

View History
  • Implied Volatility 40.55% ( +1.41%)
  • Historical Volatility 33.74%
  • IV Percentile 96%
  • IV Rank 66.33%
  • IV High 53.48% on 04/10/25
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 0.97
  • Today's Volume 8,742
  • Volume Avg (30-Day) 52,271
  • Put/Call OI Ratio 0.92
  • Today's Open Interest 578,417
  • Open Int (30-Day) 632,609

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.16
  • Number of Estimates 7
  • High Estimate 2.25
  • Low Estimate 2.10
  • Prior Year 2.07
  • Growth Rate Est. (year over year) +4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
75.93 +2.75%
on 04/16/25
Period Open: 93.11
93.11 -16.21%
on 03/24/25
-15.09 (-16.21%)
since 03/21/25
3-Month
75.93 +2.75%
on 04/16/25
Period Open: 96.24
100.15 -22.10%
on 02/03/25
-18.22 (-18.93%)
since 01/21/25
52-Week
75.93 +2.75%
on 04/16/25
Period Open: 125.78
134.63 -42.05%
on 06/25/24
-47.76 (-37.97%)
since 04/19/24

Most Recent Stories

More News
Stocks Set to Open Sharply Lower After Trump’s Push Against Powell, U.S. Economic Data and Tech Earnings in Focus

June S&P 500 E-Mini futures (ESM25) are down -1.09%, and June Nasdaq 100 E-Mini futures (NQM25) are down -1.23% this morning, pointing to a sharply lower open on Wall Street as U.S. President Donald Trump’s...

GOOGL : 147.29 (-2.56%)
AVGO : 164.21 (-3.97%)
VZ : 43.42 (-1.41%)
MRK : 77.50 (-0.64%)
TXN : 143.86 (-3.09%)
UNH : 430.45 (-5.21%)
ESM25 : 5,189.50 (-2.32%)
TSLA : 224.16 (-7.13%)
T : 26.73 (-1.55%)
IBM : 236.42 (-1.00%)
LLY : 825.15 (-1.76%)
NQM25 : 17,929.50 (-2.46%)
Streak Analysis Alert: Why Merck (MRK) Should Be on Your Radar This Week

Blue chips like MRK stock generally represent a 50/50 wager for any given week. However, certain conditions strongly tilt the odds toward one side of the spectrum.

MRK : 77.50 (-0.64%)
Where Will Eli Lilly Be in 5 Years?

What a difference five years can make. Just look at Eli Lilly (NYSE: LLY) . In April 2020, the drugmaker stood in the shadows to some extent with companies including Johnson & Johnson, Pfizer , and Merck...

NVO : 57.50 (-1.00%)
MRK : 77.50 (-0.64%)
JNJ : 157.32 (-0.10%)
LLY : 825.15 (-1.76%)
PFE : 22.04 (-0.45%)
Should You Buy, Hold, or Sell GILD Stock Ahead of Q1 Earnings?

Biotech bigwig Gilead Sciences, Inc. GILD  is scheduled to report first-quarter 2025 results on April 24, after market close. The Zacks Consensus Estimate for sales and earnings is pegged at $6.83 billion...

MRK : 77.50 (-0.64%)
GILD : 104.40 (-0.13%)
GSK : 36.08 (+0.42%)
Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

Pharmaceuticals Stocks Q4 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers

JAZZ : 99.64 (-3.06%)
VTRS : 7.53 (-0.40%)
MRK : 77.50 (-0.64%)
ANIP : 68.67 (-0.78%)
BMY : 49.06 (-0.35%)
Gilead vs Bristol Myers: Which Biotech Bigwig is a Better Bet Now?

Gilead Sciences, Inc. GILD and Bristol Myers Squibb BMY are leading biotechnology companies with broad and diverse portfolios and a global footprint.Gilead Sciences is a pioneer in developing treatments...

MRK : 77.50 (-0.64%)
GILD : 104.40 (-0.13%)
BMY : 49.06 (-0.35%)
The Zacks Analyst Blog Merck and AbbVie

For Immediate ReleasesChicago, IL – April 15, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

MRK : 77.50 (-0.64%)
ABBV : 172.04 (-0.55%)
ABBV vs. MRK: Which Drug Giant is a Better Buy Now?

Merck MRK and AbbVie ABBV are leading pharmaceutical companies with strong portfolios in oncology and immunology. While AbbVie also markets products for aesthetics, neuroscience and eye care, Merck has...

NVO : 57.50 (-1.00%)
MRK : 77.50 (-0.64%)
LLY : 825.15 (-1.76%)
ABBV : 172.04 (-0.55%)
What to Expect From Merck & Co.'s Next Quarterly Earnings Report

Merck & Co. will release its first-quarter earnings later this month, and analysts anticipate a single-digit bottom-line growth.

XLV : 133.09 (-1.77%)
$SPX : 5,164.24 (-2.24%)
MRK : 77.50 (-0.64%)
This Nvidia-Backed AI Stock Is Shrugging Off Market Pain Thanks to the FDA. Should You Buy Shares Now?

Recursion Pharmaceuticals stock rallied as FDA announces plans of using AI for drug testing. Is it too late to invest in RXRX shares?

MRK : 77.50 (-0.64%)
RXRX : 5.41 (-1.64%)
RHHBY : 38.9700 (+0.18%)
SNY : 50.75 (-0.29%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 80.74
2nd Resistance Point 79.75
1st Resistance Point 78.87
Last Price 77.50
1st Support Level 77.00
2nd Support Level 76.01
3rd Support Level 75.13

See More

52-Week High 134.63
Fibonacci 61.8% 112.21
Fibonacci 50% 105.28
Fibonacci 38.2% 98.35
Last Price 77.50
52-Week Low 75.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Unlock High-Probability Trade Setups: Master Fractals & Time Frames Like a Pro